<DOC>
	<DOCNO>NCT01089062</DOCNO>
	<brief_summary>Compare acute effect tolerability Dihydroergotamine Mesylate ( DHE ) deliver Oral Inhalation ( MAP0004 ) versus intravenous ( IV ) infusion healthy adult volunteer .</brief_summary>
	<brief_title>Pharmacodynamic Study Compare Acute Effects Dihydroergotamine Mesylate ( DHE ) Pulmonary Arterial Pressure</brief_title>
	<detailed_description />
	<mesh_term>Dihydroergotamine</mesh_term>
	<criteria>1 . Able provide sign , execute write informed consent 2 . Healthy nonsmoking adult volunteer : Male Female subject 18 45 year old 3 . Female subject practice adequate contraception 4 . Stable cardiac status 5 . Normal hemoglobin value 6 . Normal Echocardiogram 7 . Normal clinically significant 12lead Electrocardiogram 8 . Demonstrated ability properly use TempoÂ® Inhaler 9 . Subject donate blood last 56 day 1 . Contraindication dihydroergotamine mesylate ( DHE ) 2 . Use excluded concomitant medication within 10 day prior Visit 1 3 . History hemiplegic basilar migraine 4 . Participation another investigational trial 30 day prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>